CN114907431A - 一种倍他米松醋酸酯的制备方法 - Google Patents
一种倍他米松醋酸酯的制备方法 Download PDFInfo
- Publication number
- CN114907431A CN114907431A CN202210398061.2A CN202210398061A CN114907431A CN 114907431 A CN114907431 A CN 114907431A CN 202210398061 A CN202210398061 A CN 202210398061A CN 114907431 A CN114907431 A CN 114907431A
- Authority
- CN
- China
- Prior art keywords
- betamethasone
- acetate
- stirring
- preparation
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004648 betamethasone acetate Drugs 0.000 title claims abstract description 25
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims abstract description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 14
- 229960002537 betamethasone Drugs 0.000 claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 9
- 239000001632 sodium acetate Substances 0.000 claims abstract description 9
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 28
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000005457 ice water Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 4
- 239000002351 wastewater Substances 0.000 abstract description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract description 3
- 238000006555 catalytic reaction Methods 0.000 abstract description 2
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 239000012295 chemical reaction liquid Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明涉及一种倍他米松醋酸酯的制备方法，具体包括，以DMSO为溶剂，倍他米松与醋酸酐经醋酸钠催化反应成酯，反应结束后，将反应液水析，得到倍他米松醋酸酯。本发明成本低、收率高、不产生含氮废水，绿色环保，适合工业化生产要求。
Description
技术领域
本发明属于原料药合成技术领域，具体涉及倍他米松醋酸酯的合成工艺方法。
背景技术
倍他米松醋酸酯(Betamethasone 21-acetate)，化学名16β-甲基-11β,17α，21-三羟基-9α-氟-孕甾-1,4-二烯-3,20-二酮-21-醋酸酯，是糖皮质激素倍他米松的21位醋酸酯，是地塞米松醋酸酯的16位差向异构体。倍他米松醋酸酯为固醇类药物，可用于治疗多种风湿免疫性疾病，其药效同地塞米松，其抗炎作用比地塞米松、去炎松、氢化可的松强，副作用少。现多用于治疗活动性风湿病、类风湿性关节炎、红斑性狼疮、严重支气管哮喘、严重皮炎、急性白血病等。
倍他米松醋酸酯的合成工艺大致如下：
1、传统工艺(见《全国原料药工艺汇编》1980年)采用吡啶作为溶剂兼催化剂，倍他米松与醋酸酐进行21位酯化反应，此方法缺点是吡啶价格高、毒性大、严重污染环境。
2、文献(Synthetic Communications，2006，36：865-874)报道了一种制备倍他米松醋酸酯的方法，17α-羟基-9,11β-环氧-16β-甲基孕甾-1,4-二烯-3,20-二酮经21位碘代，随后经醋酸钾置换得到倍他米松醋酸酯。碘单质成本高，中间体二碘代物必须避光充氮气保存，不能长期放置，否则容易分解，同时单质碘对设备的腐蚀和存储及运输等问题限制了其在工业化生产中的使用。
3、专利CN1603333采用C3～C5的脂肪酮作溶剂，加入醋酸盐催化，由氢化可的松、醋酸、醋酸酐合成制备醋酸氢化可的松。虽用脂肪酮代替了吡啶，但工艺合成较复杂，所得产品收率较低，质量较差；溶剂用量大、成本高、无法回收等，不适用大生产。
4、专利CN101781349采用偶极非质子作溶剂，加入有机胺作催化剂(如三乙胺等)制备醋酸氢化可的松。虽该方法也能代替吡啶，但有机胺含氨氮太高，后续废水处理成本较高，且收率较低，不适用工业化生产。
5、专利CN104710494采用偶极非质子溶剂(如DMF)进行乙酰化反应，该溶剂经过反应后进入废水中，产生大量的含氮废水，不利于绿色环保。
发明内容
本发明旨在针对现有技术的不足，提供了一种较好的倍他米松醋酸酯制备方法，本发明技术方案主要包括以下步骤：
1、将DMSO、倍他米松、醋酸钠加入反应瓶中，搅拌升温反应。
2、加入醋酸酐，继续搅拌1～2h，HPLC检测倍他米松残留0.1％以下。
3、搅拌下将料液转入冰水中，控温5～15℃，搅拌1～2h，抽滤，水洗，得倍他米松醋酸酯。
所述的倍他米松醋酸酯的制备方法中，倍他米松与DMSO的质量体积比为1:3～1:8，优选1:4～1:5；倍他米松与醋酸钠的质量比为1:0:05～1:0.2，优选1:0.08～1:0.12；倍他米松与醋酸酐的质量比为1:0.3～1:1，优选1:0.4～1:0.6；反应温度为30～60℃，优选40～50℃。
本发明中的技术方案，使用DMSO作为反应溶剂，避免产生含氮废水，对生化细菌无毒副作用，环境友好，适合工业化生产要求。
具体实施方式
下面结合具体实施例对本发明作进一步详细说明，但并不限制本发明的范围，凡基于本发明上述内容所实现的技术均属于本发明的范围。
实施例1
搅拌下将DMSO 80ml、倍他米松20g、醋酸钠2g加入反应瓶中，搅拌升温至50℃，加入醋酸酐12g，继续搅拌1～2h，HPLC检测倍他米松残留0.1％以下。搅拌下将料液转入冰水中，控温5～15℃，搅拌1～2h，抽滤，滤饼用水淋洗，55℃鼓风干燥，得倍他米松醋酸酯21.2g，收率96％。
实施例2
搅拌下将DMSO 60ml、倍他米松20g、醋酸钠1g加入反应瓶中，搅拌升温至60℃，加入醋酸酐8g，继续搅拌1～2h，HPLC检测倍他米松残留0.1％以下。搅拌下将料液转入冰水中，控温5～15℃，搅拌1～2h，抽滤，滤饼用水淋洗，55℃鼓风干燥，得倍他米松醋酸酯21.4g，收率97％。
实施例3
搅拌下将DMSO 100ml、倍他米松20g、醋酸钠3g加入反应瓶中，搅拌升温至30℃，加入醋酸酐6g，继续搅拌1～2h，HPLC检测倍他米松残留0.1％以下。搅拌下将料液转入冰水中，控温5～15℃，搅拌1～2h，抽滤，滤饼用水淋洗，55℃鼓风干燥，得倍他米松醋酸酯21.0g，收率95％。
实施例4
搅拌下将DMSO 120ml、倍他米松20g、醋酸钠4g加入反应瓶中，搅拌升温至60℃，加入醋酸酐20g，继续搅拌1～2h，HPLC检测倍他米松残留0.1％以下。搅拌下将料液转入冰水中，控温5～15℃，搅拌1～2h，抽滤，滤饼用水淋洗，55℃鼓风干燥，得倍他米松醋酸酯21.4g，收率97％。
Claims (5)
1.一种倍他米松醋酸酯的制备方法，其特征在于，包括以下步骤：
1)将DMSO、倍他米松、醋酸钠加入反应瓶中，搅拌升温反应；
2)加入醋酸酐，继续搅拌1～2h，HPLC检测倍他米松残留0.1％以下；
3)搅拌下将料液转入冰水中，控温5～15℃，搅拌1～2h，抽滤，水洗，得倍他米松醋酸酯。
2.根据权利要求1所述的一种倍他米松醋酸酯的制备方法，其特征在于，倍他米松与DMSO的质量体积比为1:3～1:8。
3.根据权利要求1所述的一种倍他米松醋酸酯的制备方法，其特征在于，倍他米松与醋酸钠的质量比为1:0:05～1:0.2。
4.根据权利要求1所述的一种倍他米松醋酸酯的制备方法，其特征在于，倍他米松与醋酸酐的质量比为1:0.3～1:1。
5.根据权利要求1所述的一种倍他米松醋酸酯的制备方法，其特征在于，应温度为30～60℃。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210398061.2A CN114907431A (zh) | 2022-04-12 | 2022-04-12 | 一种倍他米松醋酸酯的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210398061.2A CN114907431A (zh) | 2022-04-12 | 2022-04-12 | 一种倍他米松醋酸酯的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114907431A true CN114907431A (zh) | 2022-08-16 |
Family
ID=82764724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210398061.2A Pending CN114907431A (zh) | 2022-04-12 | 2022-04-12 | 一种倍他米松醋酸酯的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114907431A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101397319A (zh) * | 2007-09-29 | 2009-04-01 | 天津天药药业股份有限公司 | 倍他米松及其系列产品的制备方法 |
| CN101781349A (zh) * | 2010-02-09 | 2010-07-21 | 天津市津津药业有限公司 | 醋酸氢化可的松的制备方法 |
| CN104761607A (zh) * | 2015-03-17 | 2015-07-08 | 河南利华制药有限公司 | 一种醋酸泼尼松龙的制备方法 |
| CN108752411A (zh) * | 2018-07-02 | 2018-11-06 | 河南利华制药有限公司 | 一种c21甾类21位乙酰化反应工艺 |
-
2022
- 2022-04-12 CN CN202210398061.2A patent/CN114907431A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101397319A (zh) * | 2007-09-29 | 2009-04-01 | 天津天药药业股份有限公司 | 倍他米松及其系列产品的制备方法 |
| CN101781349A (zh) * | 2010-02-09 | 2010-07-21 | 天津市津津药业有限公司 | 醋酸氢化可的松的制备方法 |
| CN104761607A (zh) * | 2015-03-17 | 2015-07-08 | 河南利华制药有限公司 | 一种醋酸泼尼松龙的制备方法 |
| CN108752411A (zh) * | 2018-07-02 | 2018-11-06 | 河南利华制药有限公司 | 一种c21甾类21位乙酰化反应工艺 |
Non-Patent Citations (1)
| Title |
|---|
| NGAMPONG KONGKATHIP等: "Synthesis of Betamethasone From the Waste of Thai Agave Sisalana" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103694306B (zh) | 一种布地奈德s异构体制备r异构体的方法 | |
| CA2670276A1 (en) | Compounds useful for treating neurodegenerative disorders | |
| DE2649097A1 (de) | Verfahren zur herstellung von corticoidderivaten und corticoidderivate | |
| CN108752411A (zh) | 一种c21甾类21位乙酰化反应工艺 | |
| CN111253457A (zh) | 一种制备16α-羟基泼尼松龙的方法 | |
| CN112876527B (zh) | 一种醋酸泼尼松母液的处理方法 | |
| CN114907431A (zh) | 一种倍他米松醋酸酯的制备方法 | |
| CN106589035A (zh) | 一种醋酸泼尼松龙的制备工艺 | |
| CN104761607A (zh) | 一种醋酸泼尼松龙的制备方法 | |
| CN110092809B (zh) | 一种利用巨大芽孢杆菌分离提取β－谷甾醇的方法 | |
| CN114276406B (zh) | 去羟米松中间体的制备方法 | |
| CN104710494B (zh) | 一种醋酸氢化可的松的生产工艺 | |
| CN105384790A (zh) | 一种泼尼松龙的制备方法 | |
| CN105367618A (zh) | 氢化可的松的制备方法 | |
| CN103421070A (zh) | 一种改进的孕甾烯类化合物c21-乙酰氧基化方法 | |
| CN101870704A (zh) | 一种头孢替坦酸粗品的纯化方法 | |
| DE10055820C1 (de) | Verfahren zur Herstellung eines Glucocorticoids | |
| CN110862431A (zh) | 一种高质量醋酸泼尼松及其中间体的制备方法 | |
| CN104292284A (zh) | 关于一种17-乙炔基-16-烯甾体衍生物的制备方法 | |
| CN114478674B (zh) | 一种二氟泼尼酯中间体的制备方法 | |
| CN111944003B (zh) | 一种可的松-21-醋酸酯的制备方法 | |
| CN115433756B (zh) | 一种泼尼松龙的制备方法 | |
| CN112358522B (zh) | 一种倍他米松二丙酸酯的精制方法及倍他米松二丙酸酯 | |
| CN109796514B (zh) | 一种由醚化后中间体制备双丙酸阿氯米松的方法 | |
| CN108752408B (zh) | 从微生物法制备雄烯二酮的固体下脚料中回收、精制雄烯二酮的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220816 |